NLRP3 and metabolic dysfunction-associated steatotic liver disease: SGLT2is have been demonstrated to reduce the production of inflammatory cytokines, such as TNF-α, MCP-1, IL-1β, and IL-6, and to attenuate the activation of the NLRP3 inflammasome in MASLD animal models [182].